Vaping, having been proved to cause cancer on mice, may not be as safe as the ads show to all and has already jeopardized the health of the young. Scientists are trying to find the causes of human cancer as well as its treatment.
The last two months have witnessed thousands of lung injury cases associated with the use of e-cigarette (also called vaping) according to the U.S. Food and Drug Administration (FDA). JUUL, a popular e-cigarettes provider among youth, used to claim itself a totally safe smoking alternative, but now is reported to be in charge of a severe collapsed lung in an 18-year-old boy.
Earlier this month, New York University released a report that exposure to nicotine from e-cigarette vapor causes DNA damage in lung and bladder of mice. Researchers found that out of 40 mice exposed to cigarette vapor with nicotine over 54 weeks, 22.5% developed lung cancer and 57.5% developed precancerous lesions on the bladder.
It is just 15 years since the first e-cigarette had been available for customers, thus little research has been done on this subject. The outbreak of lung injury cases together with NYU’s research makes lung cancer a focus of people around the world again. Scientists have focused on treatment of cancer for a long time and have explored several therapies, among which, chimeric antigen receptor-engineered T cell (CAR T) therapy has shown a promising future with its markable ability to eliminate various kinds of tumors.
Take Creative Biolabs, a world-leading service provider for immunotherapy, especially CAR-T therapy as an example. With a team of skillful Ph.D level scientists and clinicians, Creative Biolabs has years of experiences in CAR-T field, and excels in many operations, such as biomarker identification & selection, high affinity ScFv generation, CAR design and construction, virus packaging and CAR gene delivery, CAR-T in vitro assay, CAR-T preclinical in vivo assay and CAR-T clinical trial.
Since established in 2004, Creative Biolabs has collaborated with thousands of scientists working on cancer treatment and never stopped making progress. Recently, it is capable of offering four generations of CARs for the research of ovarian cancer, neuroblastoma and various types of leukemia and lymphoma. Different from previous CAR-T generations, the 4th-generation CAR-T releases transgenic immune modifiers, such as IL-12, eliminating antigen-negative cancer cells in the targeted lesion, aiming to propose a more specific solution to CAR-T therapy.
As a global company, Creative Biolabs are established leading expert in not only CAR-T therapy, but also cancer vaccine development, offering the one-stop custom services that cover the entire critical phases of cancer vaccine product discovery and development. With top facilities and cleanrooms following Good Manufacturing Practices (GMP), the company makes great efforts to meet the steadily growing demands for novel cancer vaccines.
As a reliable and trusted contract research organization in the area of cancer immunotherapy discovery and development, Creative Biolabs is working to help researchers make scientific history fighting malicious cancers.
A New Treatment Method May Cure Patients of Genetic Hearing Loss
There may be a better way to heal the genetic hearing loss.
Will Oncolytic Virotherapy Be the Winner Fighting Against Breast Cancer?
Breast cancer remains a hot issue for a long time and scientists are trying to find a better treatment.
Gene Editing Might be A Powerful Tool to Conquer Cervical Cancer
Australian researchers claimed that they have found a cure for cervical cancer in mice using gene-editing technology, which is a big breakthrough for gene therapy, and Creative Biolabs spares no effort in assisting global scientists to make greater progress.
